论文部分内容阅读
目的探讨曲美他嗪治疗老年慢性心力衰竭(CHF)的临床疗效及安全性。方法 90例老年慢性心力衰竭患者,随机分为治疗组和对照组,各45例。两组均给予常规药物治疗,在此基础上治疗组加服曲美他嗪。治疗6个月后,观察并比较两组患者临床疗效、左室舒张末期内径(LVEDD)、左室射血分数(LVEF)及药物不良反应等。结果治疗6个月后,治疗组总有效率为86.7%,对照组为63.7%,两组比较差异有统计学意义(P<0.05);治疗前两组LVEDD、LVEF比较差异无统计学意义(P>0.05);治疗后治疗组LVEDD、LVEF均优于对照组,差异具有统计学意义(P<0.05)。结论曲美他嗪治疗老年慢性心力衰竭的临床效果显著,可以有效改善患者的心功能,降低不良反应,值得临床推广。
Objective To investigate the clinical efficacy and safety of trimetazidine in elderly patients with chronic heart failure (CHF). Methods 90 elderly patients with chronic heart failure were randomly divided into treatment group and control group, 45 cases each. Both groups were given conventional drug treatment, on the basis of the treatment group plus trimetazidine. After 6 months of treatment, clinical efficacy, left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF) and adverse drug reactions were observed and compared. Results After 6 months treatment, the total effective rate was 86.7% in the treatment group and 63.7% in the control group, with significant difference between the two groups (P <0.05). There was no significant difference in LVEDD and LVEF between the two groups before treatment P> 0.05). After treatment, the LVEDD and LVEF in the treatment group were better than those in the control group, the difference was statistically significant (P <0.05). Conclusion Trimetazidine treatment of elderly patients with chronic heart failure has a significant clinical effect, which can effectively improve the patient’s cardiac function, reduce adverse reactions, is worth clinical promotion.